Tenax Therapeutics (TENX)
Develops oral levosimendan in Phase 3 trials for PH-HFpEF.
$1.92
Pre-market+0.07 (+4.07%)
At close$1.85(+2.50%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions81 holders · as of Mar 31, 2026 | 80.02% | 21.23M shares | |
| Insiders6 holders · as of Jul 14, 2026 | 0.17% | 45.6K shares | |
| Strategic holders1 holder · as of Jan 10, 2025 | 1.32% | 351.1K shares | |
| Otherremainder | 18.49% | 4.90M shares |
26.53M company shares as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Institutions13F, as of Mar 31, 2026
81 holders · 21.23M shares · 33 new positions · 59 increased · 5 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Price T Rowe Associates Inc /MD/ | 2.95M | 11.13% | +2.95Mnew | May 15, 2026 |
| Janus Henderson Group PLC | 1.82M | 6.84% | +1.65M | May 18, 2026 |
| VR Adviser, LLC | 1.68M | 6.32% | +1.68M | May 15, 2026 |
| Perceptive Advisors LLC | 1.45M | 5.46% | +1.01M | May 29, 2026 |
| Ikarian Capital, LLC | 1.02M | 3.84% | +50.0K | May 15, 2026 |
| Stonepine Capital Management, LLC | 975.2K | 3.68% | +963.3K | May 14, 2026 |
| Logos Global Management LP | 625.0K | 2.36% | +625.0Knew | May 15, 2026 |
| Morgan Stanley | 596.6K | 2.25% | +188 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 14.90% | 3.94M | 13G | Jul 8, 2026 ↗ |
| Janus Henderson Group PLC | 9.99% | 623.7K | 13G | Dec 8, 2025 ↗ |
| Adage Capital Management, L.P.incl. Robert Atchinson, Phillip Gross | 9.99% | 369.1K | 13G | Nov 12, 2024 ↗ |
| RTW Investments, LP | 9.90% | 1.87M | 13G | May 15, 2026 ↗ |
| Venrock Healthcare Capital Partners III, L.P. | 9.90% | 1.96M | 13G | May 15, 2026 ↗ |
| Vestal Point Capital, LP | 9.90% | 2.47M | 13G | Nov 14, 2025 ↗ |
| Biotechnology Value Fund L P | 9.20% | 1.75M | 13G | May 15, 2026 ↗ |
| ING Groep N.V. | 7.05% | 2.64M | 13G | Aug 27, 2026 ↗ |
| Ikarian Capital, LLC | 6.70% | 1.15M | 13G | Apr 7, 2026 ↗ |
| BlackRock, Inc. | 6.40% | 1.71M | 13G | Jul 30, 2026 ↗ |
| Millennium Management LLC | 5.80% | 2.16M | 13G | Aug 18, 2026 ↗ |
| Perceptive Advisors LLC | 5.50% | 1.45M | 13G | May 15, 2026 ↗ |
| Sphera Funds Management Ltd. | 5.33% | 1.99M | 13G | Aug 27, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 2, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 187,704 | $1.80 | 5,624,151 |
| Sep 1, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 179,058 | $1.80 | 5,436,447 |
| Aug 31, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 403,571 | $1.79 | 5,257,389 |
| Aug 24, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 107,374 | $1.75 | 4,853,818 |
| Aug 21, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 716,369 | $1.77 | 4,746,444 |
| Aug 20, 2026 | ADAR1 Capital Management, LLC10 percent owner | Purchase | 202,124 | $1.78 | 4,030,075 |
| Dec 8, 2025 | Stuart Richdirector, officer: Chief Medical Officer | Purchase | 2,500 | $10.10 | 5,000 |
| Dec 9, 2025 | Stuart Richdirector, officer: Chief Medical Officer | Purchase | 2,500 | $10.22 | 5,266 |
| Dec 2, 2025 | Stuart Richdirector, officer: Chief Medical Officer | Purchase | 1,000 | $9.01 | 1,266 |
| Dec 4, 2025 | Stuart Richdirector, officer: Chief Medical Officer | Purchase | 2,500 | $9.20 | 2,500 |
CongressHouse and Senate disclosures
Not reported.